NORWOOD, Mass. - Corbus Pharmaceuticals (NASDAQ:CRBP) Holdings, Inc. (NASDAQ: CRBP), a precision oncology company, today announced the appointment of Dr. Dominic Smethurst as Chief Medical Officer (CMO). Dr. Smethurst will play a pivotal role in the clinical development of the company's investigational oncology drugs, including CRB-701, CRB-601, and CRB-913.
Dr. Smethurst brings over two decades of experience in the pharmaceutical and biotechnology industry, having held positions at various companies and clinical research institutions. His expertise in developing novel oncology therapeutics, particularly those targeting Nectin-4, is expected to be a significant asset to Corbus as they advance their clinical trials.
The company's CEO, Yuval Cohen, Ph.D., expressed confidence in Dr. Smethurst's ability to lead the clinical and regulatory strategy, especially with the upcoming U.S. dose escalation study for CRB-701 and the dose expansion study in China conducted by partner CSPC.
CRB-701, an antibody drug conjugate targeting Nectin-4, has shown encouraging first-in-human data and is suggested to have a differentiated pharmacokinetic profile and favorable safety compared to enfortumab vedotin. Dr. Smethurst highlighted the potential of CRB-701 to deliver higher doses with improved safety and tolerability, which could be beneficial for patients with bladder cancer and other Nectin-4 rich tumors.
Corbus's pipeline also includes CRB-601, a TGFβ blocking monoclonal antibody, and CRB-913, a CB1 inverse agonist for obesity treatment. The company is committed to bringing innovative scientific approaches to well-understood biological pathways, aiming to help people defeat serious illnesses.
This announcement is based on a press release statement from Corbus Pharmaceuticals Holdings, Inc. and reflects the company's efforts to strengthen its leadership team and advance its clinical programs. The appointment of Dr. Smethurst as CMO is a strategic move to enhance the company's clinical development capabilities as they prepare for significant clinical and strategic milestones.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.